Compare Stocks: ARTV, KARD, TYRA, and TRAX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$7.03 -0.3%	$10.34	$2.71 ▼ $14.53	$344.67M	2.18	463,323 shs	450,549 shs
KARD Kardigan	$14.66 -0.8%	$19.64	$13.75 ▼ $27.00	$1.38B	N/A	812,168 shs	493,599 shs
TRAX First Tracks Biotherapeutics	$35.98 -1.8%	$41.69	$14.72 ▼ $49.91	$1.31B	N/A	713,248 shs	645,547 shs
TYRA Tyra Biosciences	$21.98 +2.5%	$26.41	$12.98 ▼ $40.65	$1.28B	0.73	1.41 million shs	500,026 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	+0.86%	-9.96%	-36.43%	-27.32%	+138.18%
KARD Kardigan	-0.07%	-9.33%	-26.17%	-38.03%	+1,477,999,900.00%
TRAX First Tracks Biotherapeutics	+6.48%	-6.00%	-12.45%	+82.16%	+3,664,999,900.00%
TYRA Tyra Biosciences	-1.42%	-16.37%	-13.99%	-32.84%	+65.38%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARTV Artiva Biotherapeutics	$7.03 -0.3%	$10.34	$2.71 ▼ $14.53	$344.67M	2.18	463,323 shs	450,549 shs
KARD Kardigan	$14.66 -0.8%	$19.64	$13.75 ▼ $27.00	$1.38B	N/A	812,168 shs	493,599 shs
TRAX First Tracks Biotherapeutics	$35.98 -1.8%	$41.69	$14.72 ▼ $49.91	$1.31B	N/A	713,248 shs	645,547 shs
TYRA Tyra Biosciences	$21.98 +2.5%	$26.41	$12.98 ▼ $40.65	$1.28B	0.73	1.41 million shs	500,026 shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARTV Artiva Biotherapeutics	+0.86%	-9.96%	-36.43%	-27.32%	+138.18%
KARD Kardigan	-0.07%	-9.33%	-26.17%	-38.03%	+1,477,999,900.00%
TRAX First Tracks Biotherapeutics	+6.48%	-6.00%	-12.45%	+82.16%	+3,664,999,900.00%
TYRA Tyra Biosciences	-1.42%	-16.37%	-13.99%	-32.84%	+65.38%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARTV Artiva Biotherapeutics	2.83	Moderate Buy	$39.00	454.77% Upside
KARD Kardigan	2.50	Moderate Buy	$42.25	188.20% Upside
TRAX First Tracks Biotherapeutics	2.77	Moderate Buy	$66.55	84.95% Upside
TYRA Tyra Biosciences	2.86	Moderate Buy	$46.89	113.33% Upside

Current Analyst Ratings Breakdown

Latest ARTV, KARD, TYRA, and TRAX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/23/2026	TYRA Tyra Biosciences	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/22/2026	TYRA Tyra Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$50.00 ➝ $40.00
9/22/2026	TYRA Tyra Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$30.00 ➝ $29.00
9/18/2026	TRAX First Tracks Biotherapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
9/18/2026	TRAX First Tracks Biotherapeutics	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
9/16/2026	TRAX First Tracks Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$100.00
9/16/2026	TRAX First Tracks Biotherapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
9/16/2026	TRAX First Tracks Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$100.00
9/16/2026	TRAX First Tracks Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$100.00
9/14/2026	KARD Kardigan	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (D)
9/10/2026	TYRA Tyra Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 9/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARTV Artiva Biotherapeutics	$250K	1,374.79	N/A	N/A	$4.48 per share	1.57
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.86 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARTV Artiva Biotherapeutics	-$83.86M	-$3.30	N/A	N/A	N/A	N/A	-53.86%	-48.16%	11/11/2026 (Estimated)
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	N/A	-$1.84	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	-$119.95M	-$2.40	N/A	N/A	N/A	N/A	-46.39%	-43.07%	11/4/2026 (Estimated)

Latest ARTV, KARD, TYRA, and TRAX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	TRAX First Tracks Biotherapeutics	-$0.74	-$0.95	-$0.21	-$0.95	N/A	N/A
8/11/2026	Q2 2026	KARD Kardigan	N/A	-$4.61	N/A	-$4.61	N/A	N/A
8/6/2026	Q2 2026	ARTV Artiva Biotherapeutics	-$0.6251	-$0.63	-$0.0049	-$0.63	N/A	N/A
8/4/2026	Q2 2026	TYRA Tyra Biosciences	-$0.6499	-$0.69	-$0.0401	-$0.69	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARTV Artiva Biotherapeutics	N/A	24.16	24.16
KARD Kardigan	N/A	N/A	N/A
TRAX First Tracks Biotherapeutics	N/A	14.28	14.28
TYRA Tyra Biosciences	N/A	14.90	14.91

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARTV Artiva Biotherapeutics	N/A
KARD Kardigan	N/A
TRAX First Tracks Biotherapeutics	N/A
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
ARTV Artiva Biotherapeutics	1.80%
KARD Kardigan	N/A
TRAX First Tracks Biotherapeutics	N/A
TYRA Tyra Biosciences	12.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARTV Artiva Biotherapeutics	115	48.89 million	48.01 million	N/A
KARD Kardigan	241	93.50 million	N/A	N/A
TRAX First Tracks Biotherapeutics	104	35.73 million	N/A	N/A
TYRA Tyra Biosciences	87	59.68 million	52.22 million	Optionable

ARTV, KARD, TYRA, and TRAX Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 29 at 5:33 PM | globenewswire.com

Bank of America Corp DE Purchases 349,732 Shares of Tyra Biosciences, Inc. $TYRA

September 26 at 3:04 AM | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Price Target of $46.89

September 25, 2026 | americanbankingnews.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stock Has Consensus Target Price of $46.89

September 25, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Down 6.7% After Analyst Downgrade

September 25, 2026 | americanbankingnews.com

Equities Analysts Set Expectations for TYRA FY2026 Earnings

September 24, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Trading Down 6.7% on Analyst Downgrade

September 23, 2026 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Price Target Lowered to $29.00 at HC Wainwright

September 22, 2026 | marketbeat.com

RA Capital Management Acquires Over 9 Million Derivative Securities in Tyra Biosciences (NASDAQ: TYRA)

September 20, 2026 | kalkinemedia.comK

Fuhrman Alan Acquires Additional 951 Shares, Holding 37,115 Tyra Biosciences Stocks Post-Award

September 20, 2026 | kalkinemedia.comK

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 17, 2026 | prnewswire.com

Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported?

September 16, 2026 | insidermonkey.com

Tyra Biosciences (TYRA) Stock May Be Priced Too Richly For Its Assets

September 16, 2026 | finance.yahoo.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyra Biosciences, Inc. - TYRA

September 15, 2026 | globenewswire.com

Squarepoint Ops LLC Purchases 43,311 Shares of Tyra Biosciences, Inc. $TYRA

September 15, 2026 | marketbeat.com

Tyra Bioscience Shares Rise After Pricing $400 Million Offering

September 14, 2026 | marketscreener.comM

Tyra Biosciences Shares Rise After $400 Million Offering Prices

September 14, 2026 | marketwatch.com

Biotech Stocks On The Move: Tyra, Nasus, Bionano & Tenaya Make Gains

September 14, 2026 | rttnews.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Time to Buy?

September 14, 2026 | marketbeat.com

Tyra Prices $400 Mln Underwritten Offering Of Stock & Warrants To Advance Dabogratinib 3x3

September 14, 2026 | rttnews.com

Tyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

September 14, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ARTV, KARD, TYRA, and TRAX Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

$7.03 -0.02 (-0.28%)

Closing price 04:00 PM Eastern

Extended Trading

$7.02 0.00 (-0.07%)

As of 07:30 PM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Kardigan NASDAQ:KARD

$14.66 -0.12 (-0.81%)

As of 04:00 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

First Tracks Biotherapeutics NASDAQ:TRAX

$35.98 -0.67 (-1.83%)

Closing price 04:00 PM Eastern

Extended Trading

$35.93 -0.05 (-0.14%)

As of 07:30 PM Eastern

First Tracks Biotherapeutics is a clinical stage biotechnology company advancing antibody therapies which modulate immune pathways implicated in autoimmune and inflammatory diseases. Its pipeline includes ANB033 and ANB101. First Tracks Biotherapeutics is based in SAN DIEGO.

Tyra Biosciences NASDAQ:TYRA

$21.98 +0.53 (+2.47%)

Closing price 04:00 PM Eastern

Extended Trading

$23.56 +1.59 (+7.21%)

As of 07:30 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTV, KARD, TYRA, and TRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTV, KARD, TYRA, and TRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTV, KARD, TYRA, and TRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTV, KARD, TYRA, and TRAX Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Kardigan NASDAQ:KARD

First Tracks Biotherapeutics NASDAQ:TRAX

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ARTV, KARD, TYRA, and TRAX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ARTV, KARD, TYRA, and TRAX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ARTV, KARD, TYRA, and TRAX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ARTV, KARD, TYRA, and TRAX Company Descriptions

Artiva Biotherapeutics NASDAQ:ARTV

Kardigan NASDAQ:KARD

First Tracks Biotherapeutics NASDAQ:TRAX

Tyra Biosciences NASDAQ:TYRA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools